Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genprex (GNPX) Cash & Equivalents (2016 - 2025)

Genprex (GNPX) has 10 years of Cash & Equivalents data on record, last reported at $1.1 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 25.87% year-over-year to $1.1 million; the TTM value through Sep 2025 reached $1.1 million, down 25.87%, while the annual FY2024 figure was $1.6 million, 76.23% down from the prior year.
  • Cash & Equivalents reached $1.1 million in Q3 2025 per GNPX's latest filing, down from $1.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $47.1 million in Q1 2021 and bottomed at $1.1 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $18.4 million, with a median of $11.7 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 103.94% in 2021, then tumbled 87.29% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $38.6 million in 2021, then plummeted by 45.76% to $21.0 million in 2022, then tumbled by 67.85% to $6.7 million in 2023, then crashed by 76.23% to $1.6 million in 2024, then crashed by 31.11% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $1.1 million in Q3 2025, $1.3 million in Q2 2025, and $3.5 million in Q1 2025.